In CKD patients, the development of hyperkalemia is not only related to daily K+ intake but also to anti-hypertensive treatments, stage of the disease and yet unknown intrinsic factors, therefore, similarly to the use of cationic resins, we think that HKA2 inhibition should be initiated in face of an increase of plasma K+ level. This evidence concerns the gene KRT32 and chronic kidney disease.